GI Cancers Symposium 2020

Complete Coverage

Longer Maintenance of QoL in BRAF V600E-Mutant Metastatic Colorectal Cancer With Triplet Regimen vs an Irinotecan-Based Regimen

The randomized, phase 3 BEACON CRC trial was a 3-arm study conducted in patients with pretreated metastatic CRC characterized by a BRAF V600E mutation.

Phase 2 Results: Pembrolizumab Shows Antitumor Activity and a Manageable Safety Profile in Anal Squamous Cell Carcinoma

This single-arm, phase 2 study of pembrolizumab in advanced solid tumor cancers did not limit patient enrollment based on tumor PD-L1 expression level.

Primary Tumor Resection Prior to Chemotherapy Does Not Improve OS in Patients With Synchronous Metastatic CRC

Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis.

Older Adults Are Less Likely to Receive Second-Line Therapy for Metastatic Colorectal Cancer, Study Reports

Even though older adults were prescribed second-line therapies less frequently than younger adults, patients had similar overall survival outcomes across age subgroups.

Sociodemographic Factors Influenced Survival in Young Adults With Colorectal Cancer

In this study, a young adult was defined as an individual who was 40 years or younger.

Study Reveals Differences Between the Genomic Profiles of Primary Tumors and Metastatic Lesions in Intrahepatic Cholangiocarcinoma

Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.

Prior Exposure to Antibiotics or Antacids Did Not Reduce Immunotherapy Response in Advanced HCC

Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.

Addition of PEGPH20 to Frontline Chemotherapy Did Not Improve Clinical Outcomes in Pancreatic Cancer Subgroup

Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.

Addition of Pegilodecakin to FOLFOX Did Not Improve OS in Metastatic Pancreatic Cancer

Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.

Study Finds Atezolizumab Plus Bevacizumab Prolongs Maintenance of QoL Compared With Sorafenib in Certain Patients With HCC

In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.

Tumor Size and Stiffness May Be Relevant Biomarkers of Response to ICIs in Hepatocellular Carcinoma

The median change in HCC tumor size between responders and nonresponders was statistically significant.

Avelumab Maintenance: No OS Benefit vs Continued Chemotherapy in HER2-Negative Gastrointestinal Cancers

Fewer treatment-related grade 3 or higher adverse events were reported in the avelumab arm compared with the chemotherapy arm.

Use of Value Pathways to Guide Treatment Decisions in Gastric Cancer Had Little Impact on Overall Survival

Although the use of value pathways in oncology appeared to extend time to treatment failure, it did not appear to influence overall survival.

Progression-Free Rate With Maintenance Therapy in Some Esophageal or Gastric Cancers May Be Associated With PD-L1 Level

In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.

No Local Control or OS Benefit Seen With RT Dose Escalation in Inoperable Esophageal Cancer

In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.

The 2020 Gastrointestinal Cancers Symposium: What to Expect

Cancer Therapy Advisor’s coverage of the Gastrointestinal Cancers Symposium will reflect the theme of personalized care across multiple types of gastrointestinal cancers.